Catalyst

Slingshot members are tracking this event:

Immune Design's (IMDZ) MEDI7510 for Respiratory Syncytial Virus Advances to Phase 2

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AZN

100%
IMDZ

100%

Additional Information

Additional Relevant Details The study will also evaluate the safety and immunogenicity of MEDI7510 or placebo and immune response to MEDI7510 in Season 1 and Season 2. The trial is expected to enroll approximately 1,900 adult subjects, 60 years or older, globally.
http://ir.immunedesi...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 29, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Medi7510, Respiratory Syncytia Virus, Medimmune, Glass Discovery Platform